Compound

Compound. Defined in the License Agreement

Compound. Means that certain pharmaceutical compound known as [***].

Compound. Means, with respect to each Licensed Product, the active pharmaceutical ingredient for such Licensed Product approved by CyDex in accordance with Section 2.5, owned by or exclusively licensed to Company and developed and manufactured by or on behalf of Company.

Compound. Each chemically distinct compound that is synthesized by Exelixis that fulfills the Quality Control Criteria on a per Plate basis and is delivered to Cytokinetics in accordance with Section 3.4

Compound. All the compounds which are selective phosphodiesterase type-5 inhibitor, which compounds are contained within a claim of any unexpired TANABE PATENT no matter when filed or in a claim of a pending application for a TANABE PATENT no matter when filed which is being prosecuted in good faith by or on behalf of TANABE or its AFFILIATE, including without limitation the compound coded as T-1790 by TANABE, chemically known as [***].

Compound. Ganaxolone (i.e., 3β-Methyl-3α-ol-5α-pregnan-20-one or 3α-Hydroxy-3β-methyl-5α-pregnan-20-one)

Compound. The amphetamine polistirex active pharmaceutical ingredient in the Neos Product of the Neos NDA as of the Effective Date

Compound. Defined in the Commercial License Agreement

Compound. Means that certain neuroactive steroid known as Allopregnanolone.

Compound. Droxidopa.